OR WAIT null SECS
September 03, 2023
Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.
September 02, 2023
European vaccine manufacturing is being boosted with high level investments.
August 23, 2023
WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.
August 17, 2023
With this agreement, Chiesi Global Rare Diseases will co-develop drug delivery systems with Aliada Therapeutics for large-molecule therapeutics that can cross the blood-brain barrier.
An mRNA conversation about the recent past, current hot topics, and probable future.
Experts discuss the promise of personalized cancer vaccines through the inherent nimbleness of mRNA platform.
August 09, 2023
SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).
August 03, 2023
The biggest hurdle is developing palatable formulations that are efficacious and patient friendly.
A comprehensive understanding of what makes mRNA vaccines tick is crucial in charting the future of the market.
August 01, 2023
In this episode, David Tisi and Reenal Gandhi provide expert insights into advances and innovations changing the drug dosage form landscape.